Copy Link Print Information

Natriuretic peptides A Antibody (YA9987)

(Synonyms: ANP, PND, NPPA, Natriuretic peptides A, Atrial natriuretic factor prohormone, Atrial natriuretic peptide prohormone, Atriopeptigen, Cardiodilatin, preproCDD-ANF, proANF, preproANP, proANP, CDD)

Natriuretic peptides A Antibody (YA9987) is a Rabbit-derived and non-conjugated IgG Monoclonal, Recombinant antibody, targeting to Natriuretic peptides A.

For research use only. We do not sell to patients.
  • Host:

    Rabbit

  • Isotype:

    IgG

  • Application:

    WB, ICC/IF

  • Reactivity :

    Human

  • Formulation:

    Supplied in PBS (pH 7.4), containing 50% glycerol, 0.2% BSA and 0.01% sodium azide.

  • Conjugation:
    Non-conjugated
  • Experimental Validation Results for Natriuretic peptides A Antibody (YA9987)
  • Natriuretic peptides A Antibody (YA9987) Product Image
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Service
Data Download
Related Products:
Top Publications Citing

Use of MCE Products

Applications

Application
WB Info
WB: Western Blot
ICC/IF Info
ICC/IF: Immunocytochemistry/
Immunofluorescence
Dilution Ratio 1:1000-2000 1:50-200

Product Details

Description

Natriuretic peptides A Antibody (YA9987) is a Rabbit-derived and non-conjugated IgG Monoclonal, Recombinant antibody, targeting to Natriuretic peptides A.

  • Host Rabbit
  • Clonality Monoclonal,Recombinant
  • Species Reactivity
    Human
  • Observed Molecular Weight
    Observed band size: 15 kDa Info
    Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
  • Calculated Molecular Weight Predicted band size: 16 kDa
Immunogen

Synthetic peptide corresponding to human ANP.

Sensitivity

Endogenous

Purification

affinity purified.

Conjugation

Non-conjugated

Modification

Unmodified

Isotype

IgG

Product Properties

  • Appearance

    Solution

  • Formulation

    Supplied in PBS (pH 7.4), containing 50% glycerol, 0.2% BSA and 0.01% sodium azide.

  • Storage & Stability

    Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

  • Shipping

    Shipping with blue ice.

Verification Images

  • Experimental Validation Results for Natriuretic peptides A Antibody (YA9987)
    Western blot analysis was performed on protein extracts (40 μg) from 293T (lane 2) using Natriuretic peptides A antibody. Proteins were transferred onto a 0.45 μm PVDF membrane using the Trans-Blot® Turbo™ system for 13 min. The membrane was then blocked with 5% nonfat milk in TBST (HY-K1025) for 1 h at room temperature. The primary antibody (1:1000) and loading control antibody GAPDH Antibody (HRP) (HY-P80954A) (1:5000) were diluted in 5% nonfat milk in TBST and incubated with the membrane overnight at 4°C. After washing, the membrane of primary antibody was incubated with HRP-conjugated goat anti-rabbit/mouse IgG secondary antibody (HY-P8001/HY-P8004) (1:5000) diluted in 5% nonfat milk in TBST for 1 h at room temperature. Protein bands were visualized using an Ultra High Sensitivity ECL detection kit (HY-K1005).

Background

  • Function

    Natriuretic peptides A is a Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism. Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses. Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance. Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts. Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis. This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue. Binds the clearance receptor NPR3 which removes the hormone from circulation[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17].

  • Subcellular Localization

    Secreted

  • Expression


    Tissue_Specificity: Detected in the kidney distal tubular cells (at protein level). Present in urine (at protein level).

  • Isoforms & Post-Translational Modification

    Natriuretic peptides A has an amino acid length of 151, molecular weight is 16396 Da.
    The precursor molecule is proteolytically cleaved by CORIN at Arg-123 to produce atrial natriuretic peptide. Undergoes further proteolytic cleavage by unknown proteases to give rise to long-acting natriuretic peptide, vessel dilator and kaliuretic peptide. In the kidneys, alternative processing by an unknown protease results in the peptide urodilatin.

  • Subunit

    Homodimer; disulfide-linked antiparallel dimer

  • SwissProt ID

    P01160

  • Gene ID
    4878 [NCBI]
  • Synonyms

    ANP, PND, NPPA, Natriuretic peptides A, Atrial natriuretic factor prohormone, Atrial natriuretic peptide prohormone, Atriopeptigen, Cardiodilatin, preproCDD-ANF, proANF, preproANP, proANP, CDD

References

[1]. Birkenfeld AL, et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab. 2005 Jun;90(6):3622-8. [Content Brief]

[2]. Rubattu S, et al. Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol. 2006 Aug 1;48(3):499-505. [Content Brief]

[3]. Birkenfeld AL, et al. Atrial natriuretic peptide induces postprandial lipid oxidation in humans. Diabetes. 2008 Dec;57(12):3199-204. [Content Brief]

[4]. Souza SC, et al. Atrial natriuretic peptide regulates lipid mobilization and oxygen consumption in human adipocytes by activating AMPK. Biochem Biophys Res Commun. 2011 Jul 8;410(3):398-403. [Content Brief]

[5]. Bordicchia M, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012 Mar;122(3):1022-36. [Content Brief]

[6]. Vesely DL, et al. Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans. Proc Soc Exp Biol Med. 1989 Dec;192(3):230-5. [Content Brief]

[7]. Vesely DL, et al. Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate the aorta. Biochem Biophys Res Commun. 1987 Nov 13;148(3):1540-8. [Content Brief]

[8]. Vesely DL, et al. Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion. J Endocrinol. 1995 Sep;146(3):373-80. [Content Brief]

[9]. Chiou S, et al. Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides. Endocrinology. 1995 May;136(5):2033-9. [Content Brief]

[10]. Vesely DL, et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation. 1994 Sep;90(3):1129-40. [Content Brief]

[11]. Sothern RB, et al. Temporal (circadian) and functional relationship between atrial natriuretic peptides and blood pressure. Chronobiol Int. 1995 Apr;12(2):106-20. [Content Brief]

[12]. Bennett BD, et al. Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera. J Biol Chem. 1991 Dec 5;266(34):23060-7. [Content Brief]

[13]. Koller KJ, et al. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science. 1991 Apr 5;252(5002):120-3. [Content Brief]

[14]. Ralat LA, et al. Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response. J Biol Chem. 2011 Feb 11;286(6):4670-9. [Content Brief]

[15]. Vesely DL, et al. Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126. Peptides. 1990 Mar-Apr;11(2):193-7. [Content Brief]

[16]. Valentin JP, et al. Urodilatin binds to and activates renal receptors for atrial natriuretic peptide. Hypertension. 1993 Apr;21(4):432-8. [Content Brief]

[17]. Lenz W, et al. Regulation of natriuretic peptide (urodilatin) release in a human kidney cell line. Kidney Int. 1999 Jan;55(1):91-9. [Content Brief]

View More

Natriuretic peptides A Antibody (YA9987) Related Classifications

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00

Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated CTLL-2 mouse cytotoxic T cells. The ED50 this effect is 0.8023 μg/ml, corresponding to a specific activity is 1246.42 units/mg.

Assay Types
  • 1/16

    MedChemExpress Validation
     Western blot analysis was performed on protein extracts (40 μg) from 293T (lane 2) using Natriuretic peptides A antibody. Proteins were transferred onto a 0.45 μm PVDF membrane using the Trans-Blot® Turbo™ system for 13 min. The membrane was then blocked with 5% nonfat milk in TBST (HY-K1025) for 1 h at room temperature. The primary antibody (1:1000) and loading control antibody GAPDH Antibody (HRP) (HY-P80954A) (1:5000) were diluted in 5% nonfat milk in TBST and incubated with the membrane overnight at 4°C. After washing, the membrane of primary antibody was incubated with HRP-conjugated goat anti-rabbit/mouse IgG secondary antibody (HY-P8001/HY-P8004) (1:5000) diluted in 5% nonfat milk in TBST for 1 h at room temperature. Protein bands were visualized using an Ultra High Sensitivity ECL detection kit (HY-K1005).

  • Natriuretic peptides A Antibody (YA9987) Product Image
    1/16
  • Experimental Validation Results for Natriuretic peptides A Antibody (YA9987)
  • Natriuretic peptides A Antibody (YA9987) Product Image
  • Experimental Validation Results for Natriuretic peptides A Antibody (YA9987)
    1/1
    MedChemExpress Validation
     Western blot analysis was performed on protein extracts (40 μg) from 293T (lane 2) using Natriuretic peptides A antibody. Proteins were transferred onto a 0.45 μm PVDF membrane using the Trans-Blot® Turbo™ system for 13 min. The membrane was then blocked with 5% nonfat milk in TBST (HY-K1025) for 1 h at room temperature. The primary antibody (1:1000) and loading control antibody GAPDH Antibody (HRP) (HY-P80954A) (1:5000) were diluted in 5% nonfat milk in TBST and incubated with the membrane overnight at 4°C. After washing, the membrane of primary antibody was incubated with HRP-conjugated goat anti-rabbit/mouse IgG secondary antibody (HY-P8001/HY-P8004) (1:5000) diluted in 5% nonfat milk in TBST for 1 h at room temperature. Protein bands were visualized using an Ultra High Sensitivity ECL detection kit (HY-K1005).
  • Experimental Validation Results for Natriuretic peptides A Antibody (YA9987)
  • Natriuretic peptides A Antibody (YA9987) Product Image
    MedChemExpress Validation

    Western blot analysis was performed on protein extracts (40 μg) from 293T (lane 2) using Natriuretic peptides A antibody. Proteins were transferred onto a 0.45 μm PVDF membrane using the Trans-Blot® Turbo™ system for 13 min. The membrane was then blocked with 5% nonfat milk in TBST (HY-K1025) for 1 h at room temperature. The primary antibody (1:1000) and loading control antibody GAPDH Antibody (HRP) (HY-P80954A) (1:5000) were diluted in 5% nonfat milk in TBST and incubated with the membrane overnight at 4°C. After washing, the membrane of primary antibody was incubated with HRP-conjugated goat anti-rabbit/mouse IgG secondary antibody (HY-P8001/HY-P8004) (1:5000) diluted in 5% nonfat milk in TBST for 1 h at room temperature. Protein bands were visualized using an Ultra High Sensitivity ECL detection kit (HY-K1005).

  • Natriuretic peptides A Antibody (YA9987) Product Image WB